| Title |
National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, December 2013
|
| DOI | 10.2147/tcrm.s52078 |
| Pubmed ID | |
| Authors |
Azuana Ramli, Syed Mohamed Aljunid, Saperi Sulong, Faridah Aryani Md Yusof |
| Abstract |
HMG-CoA reductase inhibitors (statins) are extensively used in treating hypercholesterolemia. The statins available in Malaysia include atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and fluvastatin. Over the years, they have accumulated in the National Drug Formulary; hence, the need for review. Effective selection of the best drugs to remain in the formulary can become complex due to the multiple drug attributes involved, and is made worse by the limited time and resources available. The multiattribute scoring tool (MAST) systematizes the evaluation of the drug attributes to facilitate the drug selection process. In this study, a MAST framework was developed to rank the statins based on their utilities or benefits. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| Belgium | 1 | 2% |
| Unknown | 52 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 17% |
| Student > Master | 7 | 13% |
| Student > Postgraduate | 7 | 13% |
| Student > Ph. D. Student | 7 | 13% |
| Researcher | 6 | 11% |
| Other | 5 | 9% |
| Unknown | 13 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 11% |
| Agricultural and Biological Sciences | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Nursing and Health Professions | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 19 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2013.
All research outputs
#16,722,190
of 25,374,917 outputs
Outputs from Therapeutics and Clinical Risk Management
#810
of 1,323 outputs
Outputs of similar age
#198,829
of 320,962 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#8
of 18 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,962 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.